AstraZeneca PLC - Asset Resilience Ratio
AstraZeneca PLC (AZN) has an Asset Resilience Ratio of 0.10% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of AstraZeneca PLC to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1990–2025)
This chart shows how AstraZeneca PLC's Asset Resilience Ratio has changed over time. See AstraZeneca PLC net asset quality index to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down AstraZeneca PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AstraZeneca PLC (AZN) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $115.00 Million | 0.1% |
| Total Liquid Assets | $115.00 Million | 0.10% |
Asset Resilience Insights
- Limited Liquidity: AstraZeneca PLC maintains only 0.10% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
AstraZeneca PLC Industry Peers by Asset Resilience Ratio
Compare AstraZeneca PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
AstraZeneca PLC
NASDAQ:AZN |
Drug Manufacturers - General | 0.10% |
|
Novartis AG
SW:NOVN |
Drug Manufacturers - General | 0.08% |
|
Pfizer Inc
NYSE:PFE |
Drug Manufacturers - General | 5.48% |
|
Pfizer Inc
SA:PFIZ34 |
Drug Manufacturers - General | 5.48% |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771 |
Drug Manufacturers - General | 1.97% |
|
Hubei Guangji Pharmaceutical Co Ltd
SHE:000952 |
Drug Manufacturers - General | 5.37% |
|
Firebrick Pharma Ltd
AU:FRE |
Drug Manufacturers - General | 0.29% |
|
Eli Lilly and Company
SA:LILY34 |
Drug Manufacturers - General | 8.63% |
Annual Asset Resilience Ratio for AstraZeneca PLC (1990–2025)
The table below shows the annual Asset Resilience Ratio data for AstraZeneca PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 3.87% | $4.41 Billion | $114.07 Billion | -0.28pp |
| 2024-12-31 | 4.14% | $4.31 Billion | $104.03 Billion | -0.34pp |
| 2023-12-31 | 4.48% | $4.54 Billion | $101.12 Billion | -0.52pp |
| 2022-12-31 | 5.01% | $4.83 Billion | $96.48 Billion | +4.94pp |
| 2021-12-31 | 0.07% | $69.00 Million | $105.36 Billion | -0.17pp |
| 2020-12-31 | 0.24% | $160.00 Million | $66.73 Billion | -1.14pp |
| 2019-12-31 | 1.38% | $849.00 Million | $61.38 Billion | -0.02pp |
| 2018-12-31 | 1.40% | $849.00 Million | $60.65 Billion | -0.54pp |
| 2017-12-31 | 1.94% | $1.23 Billion | $63.35 Billion | +0.53pp |
| 2016-12-31 | 1.41% | $884.00 Million | $62.53 Billion | +0.39pp |
| 2015-12-31 | 1.02% | $613.00 Million | $60.12 Billion | -0.34pp |
| 2014-12-31 | 1.36% | $795.00 Million | $58.59 Billion | -0.07pp |
| 2013-12-31 | 1.42% | $796.00 Million | $55.90 Billion | -0.11pp |
| 2012-12-31 | 1.54% | $823.00 Million | $53.53 Billion | -6.50pp |
| 2011-12-31 | 8.04% | $4.25 Billion | $52.83 Billion | +5.40pp |
| 2010-12-31 | 2.64% | $1.48 Billion | $56.13 Billion | -0.11pp |
| 2009-12-31 | 2.75% | $1.51 Billion | $54.92 Billion | +2.52pp |
| 2008-12-31 | 0.22% | $105.00 Million | $46.95 Billion | -0.15pp |
| 2007-12-31 | 0.37% | $177.00 Million | $47.96 Billion | -1.83pp |
| 2006-12-31 | 2.19% | $657.00 Million | $29.93 Billion | -4.34pp |
| 2005-12-31 | 6.54% | $1.62 Billion | $24.84 Billion | +1.87pp |
| 2004-12-31 | 4.67% | $1.20 Billion | $25.65 Billion | -8.98pp |
| 2003-12-31 | 13.65% | $3.22 Billion | $23.57 Billion | -4.71pp |
| 2002-12-31 | 18.36% | $3.96 Billion | $21.58 Billion | +1.51pp |
| 2001-12-31 | 16.85% | $4.46 Billion | $26.45 Billion | -1.75pp |
| 2000-12-31 | 18.60% | $3.43 Billion | $18.45 Billion | +4.17pp |
| 1999-12-31 | 14.43% | $2.86 Billion | $19.81 Billion | +11.38pp |
| 1998-12-31 | 3.05% | $273.88 Million | $8.98 Billion | -5.45pp |
| 1997-12-31 | 8.50% | $704.23 Million | $8.28 Billion | -5.82pp |
| 1996-12-31 | 14.32% | $1.23 Billion | $8.56 Billion | +1.97pp |
| 1995-12-31 | 12.35% | $971.94 Million | $7.87 Billion | +8.36pp |
| 1994-12-31 | 3.99% | $292.36 Million | $7.32 Billion | +1.31pp |
| 1993-12-31 | 2.69% | $199.69 Million | $7.42 Billion | -0.03pp |
| 1992-12-31 | 2.72% | $168.35 Million | $6.19 Billion | -0.10pp |
| 1991-12-31 | 2.82% | $179.63 Million | $6.36 Billion | -5.11pp |
| 1990-12-31 | 7.94% | $484.16 Million | $6.10 Billion | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more